Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
The primary objectives of the study are to use US and UK data to describe the characteristics of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic, lifestyle, clinical, and medication use.
Interventions
Tiotropium bromide + Olodaterol
DEVICESp(t)iolto® Respimat®
Sp(t)iolto® Respimat®
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* parent cohort \-- COPD diagnosis * child cohort \-- any initiation of first maintenance therapy after July 1, 2015 * grandchild cohort -- any initiation of second maintenance therapy after August 2, 2015
Exclusion criteria
\- parent cohort * age \<40 on index date * any COPD diagnosis in baseline * any use of long-acting muscarinic antagonists (LAMA), long-acting beta-agonists (LABA), or inhaled corticosteroid (ICS) in baseline * \<365 days of continuous medical and pharmacy coverage
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characteristics of Patients Receiving Second Maintenance Treatment - UK | At index date of the second maintenance treatment | Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. |
| Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US | At index date of the first maintenance treatment | The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was. |
| Characteristics of Patients Receiving First Maintenance Treatment - US | At index date of the first maintenance treatment | Characteristics of patients receiving first maintenance treatment among chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database were reported. |
| Age of Patients Receiving First Maintenance Treatment - UK | At index date of the first maintenance treatment | Age of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. |
| Characteristics of Patients Receiving First Maintenance Treatment - UK | At index date of the first maintenance treatment | Characteristics of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. |
| Age of Patients Receiving Second Maintenance Treatment - US | At index date of the second maintenance treatment | Age of patients receiving second maintenance treatment from the United States (US) IBM MarketScan database was reported. |
| Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US | At index date of the second maintenance treatment | The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was. |
| Characteristics of Patients Receiving Second Maintenance Treatment - US | At index date of the second maintenance treatment | Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United States (US) IBM MarketScan database were reported. |
| Age of Patients Receiving Second Maintenance Treatment - UK | At index date of the second maintenance treatment | Age of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. |
| Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US | At index date of cohort entry (baseline; time of COPD diagnosis). | Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the United States (US) IBM MarketScan was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015). |
| Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - UK | At index date of cohort entry (baseline; time of COPD diagnosis). | Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the the United Kingdom (UK) CPRD GOLD database was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015). |
| Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis | At index date of cohort entry (baseline; time of COPD diagnosis). | The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was. |
| Age of Patients Receiving First Maintenance Treatment - US | At index date of the first maintenance treatment | Age of chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database was reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK | At index date of the first maintenance treatment | Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. |
| Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US | At index date of the second maintenance treatment | Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database was reported. |
| Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK | At index date of the second maintenance treatment | Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. |
| Days Between Index and Initiation of First Maintenance Therapy - US | From index date until initiation of first maintenance, up to 3368 days before this study started. | Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported. |
| Days Between Index and Initiation of First Maintenance Therapy - UK | From index date until initiation of first maintenance therapy, up to 9795 days before this study started. | Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. |
| Days Between First and Second Maintenance Therapy - US | From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 1020 days before this study started. | Days between first and second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database were reported. |
| Days Between First and Second Maintenance Therapy - UK | From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 10133 days before this study started. | Days between first and second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. |
| Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US | At index date of the first maintenance treatment | Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported. |
Countries
United States
Participant flow
Recruitment details
This retrospective cohort study used previously collected administrative healthcare data (United States data from IBM MarketScan and United Kingdom data from CPRD GOLD, a primary care database) to describe the patients characteristics and treatment patterns in patients with chronic obstructive pulmonary disease (COPD), initiating tiotropium + olodaterol or other maintenance therapies.
Pre-assignment details
Patients with chronic obstructive pulmonary disease (COPD) who met all inclusion criteria and none of the exclusion criteria initiating tiotropium + olodaterol or other maintenance therapies from either IBM MarketScan (United States) or CPRD GOLD (United Kingdom) databases were included.
Participants by arm
| Arm | Count |
|---|---|
| US IBM Marketscan - Overall All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018). | 1,280,486 |
| UK CPRD GOLD - Overall All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018). | 90,660 |
| Total | 1,371,146 |
Baseline characteristics
| Characteristic | US IBM Marketscan - Overall | UK CPRD GOLD - Overall | Total |
|---|---|---|---|
| Age, Continuous | 65.3 Years STANDARD_DEVIATION 13.2 | 65.9 Years STANDARD_DEVIATION 13.5 | 65.3 Years STANDARD_DEVIATION 13.2 |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Sex: Female, Male Female | 649296 Participants | 46923 Participants | 696219 Participants |
| Sex: Female, Male Male | 631190 Participants | 43737 Participants | 674927 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 |
Outcome results
Primary
Age of Patients Receiving First Maintenance Treatment - UK
Age of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.
Time frame: At index date of the first maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Age of Patients Receiving First Maintenance Treatment - UK | 68.0 Years |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Age of Patients Receiving First Maintenance Treatment - UK | 67.0 Years |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Age of Patients Receiving First Maintenance Treatment - UK | 67.0 Years |
| UK CPRD GOLD - Overall | Age of Patients Receiving First Maintenance Treatment - UK | 67.0 Years |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Age of Patients Receiving First Maintenance Treatment - UK | 68.0 Years |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Age of Patients Receiving First Maintenance Treatment - UK | 70.0 Years |
| US IBM Marketscan - 1MT - LAMA | Age of Patients Receiving First Maintenance Treatment - UK | 68.0 Years |
| US IBM Marketscan - 1MT - LAMA+ICS | Age of Patients Receiving First Maintenance Treatment - UK | 69.0 Years |
Primary
Age of Patients Receiving First Maintenance Treatment - US
Age of chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database was reported.
Time frame: At index date of the first maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Age of Patients Receiving First Maintenance Treatment - US | 63.0 Years |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Age of Patients Receiving First Maintenance Treatment - US | 62.0 Years |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Age of Patients Receiving First Maintenance Treatment - US | 67.0 Years |
| UK CPRD GOLD - Overall | Age of Patients Receiving First Maintenance Treatment - US | 62.0 Years |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Age of Patients Receiving First Maintenance Treatment - US | 62.0 Years |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Age of Patients Receiving First Maintenance Treatment - US | 63.0 Years |
| US IBM Marketscan - 1MT - LAMA | Age of Patients Receiving First Maintenance Treatment - US | 64.0 Years |
| US IBM Marketscan - 1MT - LAMA+ICS | Age of Patients Receiving First Maintenance Treatment - US | 65.0 Years |
Primary
Age of Patients Receiving Second Maintenance Treatment - UK
Age of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.
Time frame: At index date of the second maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Age of Patients Receiving Second Maintenance Treatment - UK | 68.0 Years |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Age of Patients Receiving Second Maintenance Treatment - UK | 68.0 Years |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Age of Patients Receiving Second Maintenance Treatment - UK | 71.0 Years |
| UK CPRD GOLD - Overall | Age of Patients Receiving Second Maintenance Treatment - UK | 69.0 Years |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Age of Patients Receiving Second Maintenance Treatment - UK | 68.0 Years |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Age of Patients Receiving Second Maintenance Treatment - UK | 68.0 Years |
| US IBM Marketscan - 1MT - LAMA | Age of Patients Receiving Second Maintenance Treatment - UK | 70.0 Years |
| US IBM Marketscan - 1MT - LAMA+ICS | Age of Patients Receiving Second Maintenance Treatment - UK | 68.0 Years |
Primary
Age of Patients Receiving Second Maintenance Treatment - US
Age of patients receiving second maintenance treatment from the United States (US) IBM MarketScan database was reported.
Time frame: At index date of the second maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Age of Patients Receiving Second Maintenance Treatment - US | 64.0 Years |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Age of Patients Receiving Second Maintenance Treatment - US | 63.0 Years |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Age of Patients Receiving Second Maintenance Treatment - US | 70.0 Years |
| UK CPRD GOLD - Overall | Age of Patients Receiving Second Maintenance Treatment - US | 63.0 Years |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Age of Patients Receiving Second Maintenance Treatment - US | 63.0 Years |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Age of Patients Receiving Second Maintenance Treatment - US | 64.0 Years |
| US IBM Marketscan - 1MT - LAMA | Age of Patients Receiving Second Maintenance Treatment - US | 64.0 Years |
| US IBM Marketscan - 1MT - LAMA+ICS | Age of Patients Receiving Second Maintenance Treatment - US | 65.0 Years |
Primary
Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - UK
Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the the United Kingdom (UK) CPRD GOLD database was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015).
Time frame: At index date of cohort entry (baseline; time of COPD diagnosis).
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - UK | 65.82 Years | Standard Deviation 13.81 |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - UK | 66.17 Years | Standard Deviation 11.17 |
Primary
Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US
Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the United States (US) IBM MarketScan was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015).
Time frame: At index date of cohort entry (baseline; time of COPD diagnosis).
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US | 65.6 Years | Standard Deviation 13.3 |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US | 64.4 Years | Standard Deviation 12.8 |
Primary
Characteristics of Patients Receiving First Maintenance Treatment - UK
Characteristics of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.
Time frame: At index date of the first maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Upper respiratory tract infection | 3802 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Lower respiratory tract infection (not pneumonia) | 4835 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 2367 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral antibiotics | 5133 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral antibiotics | 480 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Lower respiratory tract infection (not pneumonia) | 501 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Upper respiratory tract infection | 454 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 207 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Upper respiratory tract infection | 166 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral antibiotics | 204 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Lower respiratory tract infection (not pneumonia) | 220 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 87 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving First Maintenance Treatment - UK | Upper respiratory tract infection | 545 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving First Maintenance Treatment - UK | Lower respiratory tract infection (not pneumonia) | 721 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 453 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral antibiotics | 796 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral antibiotics | 797 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 353 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Lower respiratory tract infection (not pneumonia) | 732 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Upper respiratory tract infection | 541 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral antibiotics | 224 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 121 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Lower respiratory tract infection (not pneumonia) | 164 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - UK | Upper respiratory tract infection | 143 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral antibiotics | 2624 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving First Maintenance Treatment - UK | Upper respiratory tract infection | 1946 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 1140 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving First Maintenance Treatment - UK | Lower respiratory tract infection (not pneumonia) | 2486 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving First Maintenance Treatment - UK | Lower respiratory tract infection (not pneumonia) | 11 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 6 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving First Maintenance Treatment - UK | Concomitant medications - Oral antibiotics | 8 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving First Maintenance Treatment - UK | Upper respiratory tract infection | 7 Participants |
Primary
Characteristics of Patients Receiving First Maintenance Treatment - US
Characteristics of patients receiving first maintenance treatment among chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database were reported.
Time frame: At index date of the first maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Pneumonia | 9946 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Lower respiratory tract infection | 8525 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Upper respiratory tract infection | 13803 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Chronic bronchitis | 5161 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Lung fibrosis | 1868 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 23272 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 37829 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oxygen therapy | 4580 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Lung fibrosis | 239 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Pneumonia | 1253 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 3172 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 5047 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Upper respiratory tract infection | 2114 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Chronic bronchitis | 603 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Lower respiratory tract infection | 1160 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oxygen therapy | 425 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 249 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Lung fibrosis | 22 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oxygen therapy | 57 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Pneumonia | 77 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 152 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Chronic bronchitis | 42 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Upper respiratory tract infection | 87 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Lower respiratory tract infection | 46 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oxygen therapy | 2094 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving First Maintenance Treatment - US | Lower respiratory tract infection | 4577 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving First Maintenance Treatment - US | Upper respiratory tract infection | 7151 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving First Maintenance Treatment - US | Chronic bronchitis | 2642 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving First Maintenance Treatment - US | Pneumonia | 4762 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving First Maintenance Treatment - US | Lung fibrosis | 882 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 12240 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 19168 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Chronic bronchitis | 502 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 4645 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Pneumonia | 1014 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Upper respiratory tract infection | 1632 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oxygen therapy | 625 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Lung fibrosis | 207 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 2770 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Lower respiratory tract infection | 885 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oxygen therapy | 305 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Lower respiratory tract infection | 367 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Pneumonia | 651 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Upper respiratory tract infection | 486 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 1508 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 929 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Lung fibrosis | 108 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving First Maintenance Treatment - US | Chronic bronchitis | 294 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving First Maintenance Treatment - US | Pneumonia | 2160 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving First Maintenance Treatment - US | Lower respiratory tract infection | 1474 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving First Maintenance Treatment - US | Chronic bronchitis | 1066 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving First Maintenance Treatment - US | Lung fibrosis | 405 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 3959 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oxygen therapy | 1058 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 7116 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving First Maintenance Treatment - US | Upper respiratory tract infection | 2299 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oxygen therapy | 16 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 50 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving First Maintenance Treatment - US | Lung fibrosis | 5 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving First Maintenance Treatment - US | Chronic bronchitis | 12 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving First Maintenance Treatment - US | Pneumonia | 29 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving First Maintenance Treatment - US | Lower respiratory tract infection | 16 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving First Maintenance Treatment - US | Upper respiratory tract infection | 34 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving First Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 96 Participants |
Primary
Characteristics of Patients Receiving Second Maintenance Treatment - UK
Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.
Time frame: At index date of the second maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 1066 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Male | 1375 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Male | 31 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 25 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Male | 51 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 36 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 152 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Male | 191 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 356 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Male | 555 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Male | 383 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 385 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Male | 127 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 71 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Male | 37 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Concomitant medications - Oral corticosteroids | 41 Participants |
Primary
Characteristics of Patients Receiving Second Maintenance Treatment - US
Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United States (US) IBM MarketScan database were reported.
Time frame: At index date of the second maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lung fibrosis | 388 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 4065 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lower respiratory infections | 1385 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Male | 3674 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Upper respiratory tract infection | 1842 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Chronic bronchitis | 1095 Participants |
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 5399 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 481 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lung fibrosis | 37 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Upper respiratory tract infection | 196 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lower respiratory infections | 130 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Chronic bronchitis | 89 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Male | 265 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 355 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lung fibrosis | 11 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 64 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Chronic bronchitis | 11 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Upper respiratory tract infection | 25 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Male | 41 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 44 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lower respiratory infections | 13 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving Second Maintenance Treatment - US | Chronic bronchitis | 264 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 1399 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving Second Maintenance Treatment - US | Upper respiratory tract infection | 497 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 1019 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lower respiratory infections | 368 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving Second Maintenance Treatment - US | Male | 920 Participants |
| UK CPRD GOLD - Overall | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lung fibrosis | 101 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Chronic bronchitis | 165 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Male | 628 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Upper respiratory tract infection | 307 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lower respiratory infections | 213 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lung fibrosis | 43 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 595 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 833 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Chronic bronchitis | 297 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 1388 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lung fibrosis | 105 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lower respiratory infections | 372 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 1125 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Upper respiratory tract infection | 442 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Characteristics of Patients Receiving Second Maintenance Treatment - US | Male | 998 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving Second Maintenance Treatment - US | Upper respiratory tract infection | 343 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving Second Maintenance Treatment - US | Male | 749 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 851 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lung fibrosis | 79 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 1126 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lower respiratory infections | 260 Participants |
| US IBM Marketscan - 1MT - LAMA | Characteristics of Patients Receiving Second Maintenance Treatment - US | Chronic bronchitis | 243 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral antibiotics | 108 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving Second Maintenance Treatment - US | Chronic bronchitis | 26 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving Second Maintenance Treatment - US | Concomitant medications - Oral corticosteroids | 75 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving Second Maintenance Treatment - US | Male | 73 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lower respiratory infections | 29 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving Second Maintenance Treatment - US | Lung fibrosis | 12 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Characteristics of Patients Receiving Second Maintenance Treatment - US | Upper respiratory tract infection | 32 Participants |
Primary
Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis
The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.
Time frame: At index date of cohort entry (baseline; time of COPD diagnosis).
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan (contained data collected from January 1, 2008 to March 31, 2018) and the United Kingdom (UK) CPRD GOLD databases (contained data collected from November 21, 1987 to June 30, 2018). Results were reported by overall and by stratified groups according to Tiotropium + Olodaterol approval date for US and UK datasets, respectively.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis | 1.6 Score on a scale | Standard Deviation 1.9 |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis | 1.5 Score on a scale | Standard Deviation 1.9 |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis | 1.9 Score on a scale | Standard Deviation 2.1 |
| UK CPRD GOLD - Overall | Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis | 1.89 Score on a scale | Standard Deviation 1.38 |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis | 1.83 Score on a scale | Standard Deviation 1.32 |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis | 2.31 Score on a scale | Standard Deviation 1.66 |
Primary
Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US
The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.
Time frame: At index date of the first maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US | 2.0 Score on a scale |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US | 2.0 Score on a scale |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US | 2.0 Score on a scale |
| UK CPRD GOLD - Overall | Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US | 2.0 Score on a scale |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US | 2.0 Score on a scale |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US | 2.0 Score on a scale |
| US IBM Marketscan - 1MT - LAMA | Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US | 2.0 Score on a scale |
| US IBM Marketscan - 1MT - LAMA+ICS | Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US | 2.0 Score on a scale |
Primary
Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US
The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.
Time frame: At index date of the second maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US | 2.0 Score on a scale |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US | 2.0 Score on a scale |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US | 3.0 Score on a scale |
| UK CPRD GOLD - Overall | Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US | 2.0 Score on a scale |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US | 2.0 Score on a scale |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US | 2.0 Score on a scale |
| US IBM Marketscan - 1MT - LAMA | Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US | 3.0 Score on a scale |
| US IBM Marketscan - 1MT - LAMA+ICS | Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US | 2.0 Score on a scale |
Secondary
Days Between First and Second Maintenance Therapy - UK
Days between first and second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.
Time frame: From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 10133 days before this study started.
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Days Between First and Second Maintenance Therapy - UK | 218.0 Days |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Days Between First and Second Maintenance Therapy - UK | 239.5 Days |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Days Between First and Second Maintenance Therapy - UK | 141.0 Days |
| UK CPRD GOLD - Overall | Days Between First and Second Maintenance Therapy - UK | 155.5 Days |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Days Between First and Second Maintenance Therapy - UK | 284.0 Days |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Days Between First and Second Maintenance Therapy - UK | 197.0 Days |
| US IBM Marketscan - 1MT - LAMA | Days Between First and Second Maintenance Therapy - UK | 225.5 Days |
| US IBM Marketscan - 1MT - LAMA+ICS | Days Between First and Second Maintenance Therapy - UK | 158.0 Days |
Secondary
Days Between First and Second Maintenance Therapy - US
Days between first and second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database were reported.
Time frame: From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 1020 days before this study started.
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Days Between First and Second Maintenance Therapy - US | 160.0 Days |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Days Between First and Second Maintenance Therapy - US | 181.5 Days |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Days Between First and Second Maintenance Therapy - US | 176.0 Days |
| UK CPRD GOLD - Overall | Days Between First and Second Maintenance Therapy - US | 158.0 Days |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Days Between First and Second Maintenance Therapy - US | 223.0 Days |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Days Between First and Second Maintenance Therapy - US | 143.5 Days |
| US IBM Marketscan - 1MT - LAMA | Days Between First and Second Maintenance Therapy - US | 137.0 Days |
| US IBM Marketscan - 1MT - LAMA+ICS | Days Between First and Second Maintenance Therapy - US | 125.0 Days |
Secondary
Days Between Index and Initiation of First Maintenance Therapy - UK
Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.
Time frame: From index date until initiation of first maintenance therapy, up to 9795 days before this study started.
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Days Between Index and Initiation of First Maintenance Therapy - UK | 28.5 Days |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Days Between Index and Initiation of First Maintenance Therapy - UK | 708.0 Days |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Days Between Index and Initiation of First Maintenance Therapy - UK | 43.5 Days |
| UK CPRD GOLD - Overall | Days Between Index and Initiation of First Maintenance Therapy - UK | 32.0 Days |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Days Between Index and Initiation of First Maintenance Therapy - UK | 19.0 Days |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Days Between Index and Initiation of First Maintenance Therapy - UK | 19.0 Days |
| US IBM Marketscan - 1MT - LAMA | Days Between Index and Initiation of First Maintenance Therapy - UK | 22.0 Days |
| US IBM Marketscan - 1MT - LAMA+ICS | Days Between Index and Initiation of First Maintenance Therapy - UK | 19.0 Days |
Secondary
Days Between Index and Initiation of First Maintenance Therapy - US
Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported.
Time frame: From index date until initiation of first maintenance, up to 3368 days before this study started.
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Days Between Index and Initiation of First Maintenance Therapy - US | 158.0 Days |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Days Between Index and Initiation of First Maintenance Therapy - US | 242.0 Days |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Days Between Index and Initiation of First Maintenance Therapy - US | 233.0 Days |
| UK CPRD GOLD - Overall | Days Between Index and Initiation of First Maintenance Therapy - US | 165.0 Days |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Days Between Index and Initiation of First Maintenance Therapy - US | 116.0 Days |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Days Between Index and Initiation of First Maintenance Therapy - US | 78.0 Days |
| US IBM Marketscan - 1MT - LAMA | Days Between Index and Initiation of First Maintenance Therapy - US | 136.0 Days |
| US IBM Marketscan - 1MT - LAMA+ICS | Days Between Index and Initiation of First Maintenance Therapy - US | 85.0 Days |
Secondary
Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK
Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.
Time frame: At index date of the first maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK | 5942 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK | 498 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK | 275 Participants |
| UK CPRD GOLD - Overall | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK | 712 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK | 960 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK | 207 Participants |
| US IBM Marketscan - 1MT - LAMA | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK | 3281 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK | 9 Participants |
Secondary
Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US
Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported.
Time frame: At index date of the first maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US | 26242 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US | 3518 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US | 183 Participants |
| UK CPRD GOLD - Overall | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US | 12483 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US | 3818 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US | 676 Participants |
| US IBM Marketscan - 1MT - LAMA | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US | 5515 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US | 49 Participants |
Secondary
Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK
Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.
Time frame: At index date of the second maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK | 1351 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK | 34 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK | 63 Participants |
| UK CPRD GOLD - Overall | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK | 172 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK | 590 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK | 299 Participants |
| US IBM Marketscan - 1MT - LAMA | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK | 144 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK | 49 Participants |
Secondary
Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US
Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database was reported.
Time frame: At index date of the second maintenance treatment
Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US | 2361 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US | 226 Participants |
| US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US | 29 Participants |
| UK CPRD GOLD - Overall | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US | 684 Participants |
| UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US | 426 Participants |
| UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US | 505 Participants |
| US IBM Marketscan - 1MT - LAMA | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US | 451 Participants |
| US IBM Marketscan - 1MT - LAMA+ICS | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US | 40 Participants |